What ShockWave Medical Investors Should Keep in Mind

By Scott Lee • Thursday, January 11 09:48 • Permanent Link

Join us for a quick overview of ShockWave Medical, a Medical Instruments & Supplies company whose shares moved 0.1% today. Here are some facts about the stock that should help you see the bigger picture:

ShockWave Medical has moved 9.3% over the last year, and the S&P 500 logged a change of 20.1%
SWAV has an average analyst rating of buy and is -5.76% away from its mean target price of $232.45 per share
Its trailing earnings per share (EPS) is $6.41
ShockWave Medical has a trailing 12 month Price to Earnings (P/E) ratio of 34.2 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $4.44 and its forward P/E ratio is 49.3
The company has a Price to Book (P/B) ratio of 13.44 in contrast to the S&P 500's average ratio of 2.95
ShockWave Medical is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
SWAV has reported YOY quarterly earnings growth of 0.0% and gross profit margins of 0.9%
The company has a free cash flow of $96.33 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
ShockWave Medical, Inc., a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.